Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
- SGLT-2 Inhibitors Safer and More Effective Than DPP-4s For Heart
- Benefits of CGM’s for Type 1 Patients
- CGM Use For Type 1 Pregnant Women Randomized Trial- CONCEPTT Study
- Fat and Carbohydrate Intake Affects CVD and Mortality
- Can Screening for Diabetes Reduce CVD and Mortality in General Population?
- Exclusive: Todd Hobbs on Novo Nordisk’s Diabetes & Obesity Projects
Letter from the Editor
It is kind of funny that just a little over 4 years ago the idea that the kidneys had anything to do with causing diabetes was not in the realm of medical practice. “Way back” then only the opposite was imagined: that diabetes affected the kidneys.
Then Invokana was introduced and the kidney’s effect on diabetes became real. The use of SGLT-2 inhibitors joined DPP-4 inhibitors as the new darlings of the oral medication diabetes world.
Over these past 4 years the SGLT-2’s have also been shown to have cardiovascular protectivity, as well as blood pressure lowering and weight loss. This week we have a great study from Cardiovascular Diabetology conducted by Anthem, Inc. and HealthCore that shows the value of using this class of drugs for their ability to decrease cardiac incidents as well as decreasing hospitalization.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
This Week's Survey
Do you feel that continuous blood glucose monitoring (CGM) will eventually replace blood glucose monitors?
Follow the link to share your response.
Tool: Medication Chart of Drugs That Raise Blood Pressure
Get our newest helpful chart, Medications that Raise Blood Pressure. Download it here (pdf).
Current Interview
Dr. Todd Hobbs is Vice President and Chief Medical Officer for Novo Nordisk in North America, where he leads the organization’s focus on the implications of diabetes for the patient, healthcare system, and healthcare professionals. He provides overall medical guidance to Novo Nordisk’s diabetes and obesity-related projects. Prior to working at Novo Nordisk, Dr. Hobbs had established a clinical practice based in Louisville, Kentucky, focusing on the intensive management of patients with diabetes of all ages, and served as chairman of the medicine department for a large regional medical center in Kentucky. During this 10year clinical career, he cared for more than 2,500 adults and children with diabetes, including outpatient and inpatient care, as well as intensive care.
Test Your Knowledge
The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) list a hierarchy of usage for antihyperglycemic medications after metformin. Which one of the following lists shows the correct hierarchy, beginning with the most preferred?
A. A Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, thiazolidinediones (TZDs), basal insulins
B. SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 RAs, TZDs, basal insulins
C. TZDs, GLP-1 RAs, SGLT-2 inhibitors, DPP-4 inhibitors, basal insulins
D. GLP-1 RAs, SGLT-2 inhibitors, basal insulins, DPP-4 inhibitors, TZDs
Follow the link to see the right answer.
Did You Know: Research Shows How A Patch Eliminates "Love Handles" and Reduces Glucose
Might this product be a noninvasive alternative to liposuction?
In a new study, scientists describe the development of a skin patch that has the potential to “melt” the most dangerous abdominal away. Researchers reveal how the novel patch delivered fat-browning drugs directly to the so-called love handles of obese mice. This not only reduced the amount of excess fat in the rodents by a fifth, but it also led to a reduction in fasting blood glucose levels. Study co-leader Li Qiang, Ph.D., of the Columbia University Medical Center in New York City, NY, and colleagues say that while the patch is yet to be tested in humans, the current study brings us closer to a noninvasive technique for the treatment of obesity and diabetes. The skin patch works by converting “bad” white fat into “good” brown fat. White fat, also called white adipose tissue, is a type of fat the body stores as an energy reserve. However, having too much of this fat, particularly around the abdominal region, can raise the risk of numerous health problems, including obesity, diabetes, and heart disease. Brown fat, or brown adipose tissue, is preferable to white fat as it burns energy. With this in mind, researchers have been searching for strategies to increase brown fat in humans, with the aim of lowering the risk of obesity and its associated health conditions. — The researchers recently reported their findings in the journal ACS Nano.
New study finds lower occurrence of heart failure in older people with type 2.
Real-time monitoring produces significant long-term improvement in HbA1c.
Study examined effectiveness of CGM on maternal glucose control and obstetric and neonatal health outcomes.
The pendulum has swung from too much fat to too many carbs.
Even though screening the general population does not impact mortality or CVD incidence, it did have benefits for those diagnosed with diabetes.
Quote of the Week!
“Have patience. All things are difficult before they become easy.”
…Saadi
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com